CHLITINA-KY (4137) reported revenue of NT$370 million for Oct 2026, +3.9% year on year and -22.7% from the previous month. Revenue for Jan–Oct 2026 was NT$3.36 billion (+7.2% year on year).
In Oct 2026, it ranked No. 25 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$370 million | +3.9% | -22.7% |
| Sep 2026 | NT$478.8 million | +22.0% | +66.2% |
| Aug 2026 | NT$288 million | -10.7% | -9.6% |
| Jul 2026 | NT$318.6 million | +2.8% | -8.8% |
| Jun 2026 | NT$349.4 million | +22.6% | +22.5% |
| May 2026 | NT$285.2 million | -14.6% | -18.2% |
| Apr 2026 | NT$348.8 million | +4.5% | +1.5% |
| Mar 2026 | NT$343.5 million | +3.7% | +75.3% |
| Feb 2026 | NT$195.9 million | -32.9% | -48.3% |
| Jan 2026 | NT$378.6 million | +117.2% | -2.4% |
| Dec 2025 | NT$387.9 million | +10.9% | +8.2% |
| Nov 2025 | NT$358.5 million | +5.5% | +0.7% |
| Oct 2025 | NT$356.2 million | +5.5% | -9.2% |
| Sep 2025 | NT$392.4 million | +4.8% | +21.6% |
| Aug 2025 | NT$322.6 million | -2.1% | +4.1% |
| Jul 2025 | NT$310 million | -2.8% | +8.8% |
| Jun 2025 | NT$285 million | -5.9% | -14.7% |
| May 2025 | NT$333.9 million | -10.9% | +0.0% |
| Apr 2025 | NT$333.9 million | -2.0% | +0.8% |
| Mar 2025 | NT$331.4 million | -12.6% | +13.5% |
| Feb 2025 | NT$292.1 million | +17.4% | +67.5% |
| Jan 2025 | NT$174.4 million | -52.9% | -50.1% |
| Dec 2024 | NT$349.7 million | -11.0% | +2.9% |
| Nov 2024 | NT$339.9 million | -19.7% | +0.6% |
| Oct 2024 | NT$337.7 million | -18.2% | -9.8% |
Jan–Oct 2026 cumulative: NT$3.36 billion (+7.2% YoY)
Other Biotech & Medical companies
Compare with peers: CHLITINA-KY vs PEC / CHLITINA-KY vs Lotus Pharm / CHLITINA-KY vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16